Cell therapy developmentWhat it doesMyoPax is developing new therapeutic approaches for genetic muscle-wasting diseases that combine regenerative muscle stem cell therapies with precise gene repair using…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Why it mattersMyoPax's Pre-Seed financing places it within an active flow of Unclassified funding, although the recorded $0M amount limits assessment of its round size.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.